Veritas Intercontinental operates in Europe, Latin America, Japan and the United Arab Emirates. Its mission is to promote the Whole Genome Sequencing, bringing genetics closer to people, allowing them to obtain information that empowers them to maximize the quality and duration of their lives and that of their families, changing the way the world conceives genetics. Veritas was the first company to offer full-scale genome sequencing and interpretation and with its physicians leads the field of genetics, pushing the boundaries of science with the latest technology to reduce the cost of the genome. Veritas was founded in 2014 by genomics experts from the world-renowned Harvard Medical School, operating worldwide from its offices in the United States, Europe, Latin America and China. The company has been recognized by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the World's Most Innovative Healthcare Companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018 and 2019. In 2018, a leading group of genetic experts founded Veritas Intercontinental, expanding Veritas technology to the international market, and developing new fundamental products of personalized precision medicine.